Press Releases

There is concern that mastectomy is over-utilized in the United States, which raises questions about the role of surgeons and patient preference in treatment selection for breast cancer. New data from an observational study published in the October 14 issue of the Journal of the American Medical Association, a theme issue on surgical care, found that breast-conserving surgery was presented and provided in the majority of patients evaluated.

Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan Kettering Cancer Center.

Memorial Sloan Kettering Cancer Center physician-scientist Charles L. Sawyers has been named a recipient of the 2009 Lasker~DeBakey Award for Clinical Medical Research.

Investigators at Memorial Sloan Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

New research led by investigators at Memorial Sloan Kettering Cancer Center sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered.

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC).

A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon.

Charles Sawyers, MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center and a Howard Hughes Medical Institute investigator, has been named a "Dream Team" leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women's cancers.